Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays.
Auteur : van der Veere PJ, van Harten AC, van Maurik IS, Teunissen CE, Barkhof F, Vos SJB, Froelich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Frisoni GB, Spiru L, Freund-Levi Y, Wallin ÅK, Hampel H, Tsolaki M, Kłoszewska I, Mecocci P, Vellas B, Lovestone S, Galluzzi S, Herukka SK, Santana I, Baldeiras I, de Mendonca A, Silva D, Chetelat G, Poisnel G, Visser PJ, Johnson SC, Stormrud E, Hansson O, Palmqvist S, Piñol-Ripoll G, , Berkhof J, van der Flier WM
Année : 2026
Journal : Alzheimers Dement 1552-5279
PubMed Id : 41657128
Automated cerebrospinal fluid (CSF) biomarker assays have largely replaced manual immunoassays for measuring amyloid pathology in CSF. We refitted and validated the ABIDE model, predicting progression from mild cognitive impairment (MCI) to dementia, with CSF measurements from the automated Elecsys platform.
